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Lafora disease (LD; OMIM 254780), one of the genetic
progressive myoclonus epilepsies (PME), is a fatal autosomal
recessive disorder. LD is characterized by periodic acid-Schiff
positive (PAS+) staining intracellular inclusion bodies, which are
pathognomic of the disease.
Symptoms of LD are expressed in early adolescence and include
generalized, mostly stimulus-sensitive, tonic–clonic and myoclon-
ic seizures as well as absences. Progressive dementia, psychosis,
cerebellar ataxia, dysarthria, amaurosis, mutism, muscle wasting
and respiratory failure develop later and lead to death usually
within a decade of the symptoms’ onset.
The genetic basis of LD is attributed to two different genes. The
EPM2A gene is located on chromosome 6q241 and encodes laforin,
while the EPM2B gene located on chromosome 6p22 encodes for
malin, an E3 ubiquitin ligase.2
The disease is treated symptomatically as there is no preventive
treatment or cure.
2. Case study
Our report shall refer to the case of a young girl with no
apparent symptoms of neurological disease until the age of 13. At* Corresponding author at: Department of Neurology, Medical School, University
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http://dx.doi.org/10.1016/j.seizure.2012.12.014that age, she manifested absence seizures (brief starring spells) and
visual auras with colorful ﬂashes lasting a few seconds. Seizures’
frequency was no more than 1–2/week and they were triggered
during eating or while watching TV or other ﬂashing lights. A few
months later, she developed generalized tonic–clonic seizures.
During the same time, a decline in her school performance was
evident along with generalized shortfall in her cognitive function.
She was treated with valproic acid, but it failed to control seizures
adequately. Two years later, myoclonic seizures were added to her
clinical manifestations and soon evolved as the most prominent
seizure type. Her cognitive decline was advancing so fast, that the
patient had to drop out of school 3 years after the onset of the
symptoms. All known antiepileptic drugs were tried in different
combinations but none was to prove effective.
Today, she is 24 years old and suffers from repeated myoclonic
seizures, which are triggered by every possible stimulus (visual,
auditory, tactile or through her being moved). Her cognitive
decline is so severe that the patient has lost the ability to
communicate verbally and she can pronounce some words with
great difﬁculty, in an incomprehensible, dysarthric way. Her
parents claim that the patient can still recognize members of her
family, as can be inferred by her emotional responses. She is
heavily disabled, suffering severe tetraparesis with no ability to
stand on her own. She has lost control of her sphincters, is
bedridden and totally dependent.
The patient’s ECG has been abnormal since the manifestation of
her symptoms. The most recent ECG showed a total absence of a
well-organized alpha rhythm. Regarding non-epileptiform ﬁnd-
ings, diffuse theta and delta waves were evident while epileptiform
activity was characterized by generalized spike-wave complexes,
coinciding with photosensitivity.
An MRI brain scan, conducted during the onset of the
symptoms, was normal. Another one, performed one year later,
revealed bilateral Ammon’s horn sclerosis and excessive brain
atrophy.
Myoclonic epilepsy was considered a possible diagnosis and a
skin biopsy was performed, yielding no obvious histopathological
ﬁndings. The diagnosis was established at the age of 19 by gene
sequencing, which identiﬁed an homozygous mutation in the
EPM2A gene. Analysis was performed by PCR ampliﬁcation of
genomic DNA, followed by automated uni-directional DNA
sequencing of the entire coding region, including the highlyvier Ltd. All rights reserved.
Fig. 1. A schematic representation of laforin protein showing its two domains and
the position of the mutation. CBD, carbohydrate binding domain; DSPD, dual-
speciﬁty phosphatase domain.
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junctions for all coding exons.
The patient is homozygous for a nonsense G > A mutation at
nucleotide 861 of the EPM2A gene. This mutation causes an amino-
acid substitution at position 287 of the laforin protein. Tryptophan
is replaced by a stop codon, resulting in a truncated protein,
potentially responsible for the clinical presentation of epilepsy in
our patient.
Three years after the initiation of the patient’s seizures and
while no diagnosis had been made, her older brother and her only
sibling in the family, developed the same symptomatology at the
age of 17. His deterioration was much more accelerated with
frequent episodes of status epilepticus (SE). During an episode of SE,
two years after his symptoms’ onset, he died. Unfortunately, no gene
analysis had been sent before his death, although it was quite clear
that the two siblings had been suffering from the same disease.
Both parents, presumed carriers of the mutation, originate from
an area with an isolated population in Northwest Greece, imposing
an increased risk for consanguinity. Unfortunately, their consent
for gene analysis has not been granted and the presence of the
mutation in their DNA samples cannot be conﬁrmed.
To our knowledge, this is a new mutation associated with the
Lafora disease, further expanding the range of identiﬁed mutations
and providing new insights into the genotype-phenotype associa-
tion for this disease.
3. Discussion
In the above described case, a new mutation in the EPM2A gene
found in Northwest Greece is causing an amino-acid substitution
at position 287 of the laforin protein (Fig. 1). More speciﬁcally,
tryptophan is replaced by a stop codon, resulting in a truncated
protein, potentially responsible for the clinical presentation of
epilepsy in our patient.
Laforin is a dual-speciﬁcity protein phosphatase, encoded by
the EPM2A gene, which is composed of 4 exons.3 The N-terminal
carbohydrate binding domain (CBD) is encoded mainly by exon 1,
while the dual-speciﬁcity phosphatase domain (DSPD) by exons 3
and 4.4 Laforin interacts with malin, a ubiquitin ligase protein
encoded by the EPM2B gene located on chromosome 6p22. Malin
polyubiquitinates laforin leading to its degradation.5
The EPM2A gene, located on chromosome 6q24, has been
associated with a wide spectrum of mutations. A recent meta-
analysis presented a list of 100 distinct mutations.6 Missense and
nonsense mutations are responsible for 60% of point mutations of
the EPM2A gene, while insertion mutations account for 13% of the
total. Deletion mutations are also common in the EPM2A gene, with
23 families reported to have large deletions. One third of the total
known mutations are clustered in exon 1, while the presence of
mutations is lower in exons 2 and 3. Exons 1 and 4 encode the
functional domains of laforin and mutations in these regions can
have a critical impact on laforin’s functionality. Our novel mutation
is located at nucleotide 861, which is located on exon 4 and leads to
a stop codon near the DSPD region.
The function of the laforin-malin complex is not clearly
understood and many different theories have been proposed. As
glycogen is a branched glucose polymer containing small amounts
of phosphate, the lack of laforin’s dephosphorylation activity may
lead to increases in phosphate content, causing abnormal
branching, which subsequently results in insoluble Lafora bodies
formation. A recent study7 reported a 40% increase of glycogen
phosphate content in liver and a 4-fold elevation in muscle using
an Epm2a/ mouse model. Still, other pathophysiologic path-
ways may be implicated in the Lafora disease occurrence.
Currently, evidence supports a critical role of the laforin-malin
complex in cellular protein clearance.8 A recent study revealed thepresence of enlarged lysosomes, lipofuscin granules, amyloid b-
peptides and insoluble ubiquitinated protein, in a laforin-deﬁcient
mice model, supporting the hypothesis of cellular degradative
pathway impairment.9 Furthermore, it has been shown that lack of
laforin in an EPM2A knockout mice model suggests a cooperative
role for the laforin-malin complex in relieving endoplasmic
reticulum stress and cell apoptosis.10
Lafora bodies can be found in neurons, skin, bone, muscles and
internal organs, such as the liver. They can be detected in skin
biopsies using PAS+ or Alcian blue staining. Skin biopsy remains a
widely used method for diagnosis due to its convenience, low cost
and minimal invasiveness. Still, there are some drawbacks, as the
absence of Lafora inclusion bodies cannot exclude the diagnosis.
This makes genetic conﬁrmation necessary for a conclusive
diagnosis.
Although Lafora bodies are a hallmark of the disease, data seem
to support that they are not a causal factor of neuronal
degeneration and epileptogenesis, but the consequence of defects
in the same physiological pathway which leads to epileptic
seizures, as reported in a study of the EPM2A gene knocked mice.3
However, using a similar Epm2a/ mouse model, a recent study7
has reported increases in glycogen phosphate content in liver and
muscles resulting in impaired glycogen branching and insoluble
particle formation. Authors support that as phosphate over-
accumulation in glycogen may be a slow process, this may explain
the late onset of symptoms in Lafora disease.
4. Conclusion
Herein, we present a new mutation near the DSPD region of
laforin protein in a homozygosity state causing the Lafora disease
phenotype. Although the detection of Lafora bodies is widely used,
genetic analysis may more decisive in diagnosis conﬁrmation and
further explores genotype-phenotype interactions in novel muta-
tions.
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